T
Toshirou Nishida
Researcher at Osaka University
Publications - 281
Citations - 16334
Toshirou Nishida is an academic researcher from Osaka University. The author has contributed to research in topics: GiST & Cancer. The author has an hindex of 50, co-authored 267 publications receiving 14773 citations. Previous affiliations of Toshirou Nishida include Osaka Medical College.
Papers
More filters
Journal ArticleDOI
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.
Seiichi Hirota,Koji Isozaki,Yasuhiro Moriyama,Koji Hashimoto,Toshirou Nishida,Shingo Ishiguro,Kiyoshi Kawano,Masato Hanada,Akihiko Kurata,Masashi Takeda,Ghulam Muhammad Tunio,Yuji Matsuzawa,Yuzuru Kanakura,Yasuhisa Shinomura,Yukihiko Kitamura +14 more
TL;DR: Sequencing of c-kit complementary DNA from five GISTs revealed mutations in the region between the transmembrane and tyrosine kinase domains, suggesting that the mutations contribute to tumor development.
Journal ArticleDOI
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri,Peter Reichardt,Yoon-Koo Kang,Jean-Yves Blay,Piotr Rutkowski,Hans Gelderblom,Peter Hohenberger,Michael F. Leahy,Margaret von Mehren,Heikki Joensuu,Giuseppe Badalamenti,Martin E. Blackstein,Axel Le Cesne,Patrick Schöffski,Robert G. Maki,Sebastian Bauer,Binh Bui Nguyen,Jianming Xu,Toshirou Nishida,John Chung,Christian Kappeler,Iris Kuss,D. Laurent,Paolo G. Casali +23 more
TL;DR: The results of this study show that oral regorafenib can provide a significant improvement in progression-free survival compared with placebo in patients with metastatic GIST after progression on standard treatments.
Journal ArticleDOI
Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts
Heikki Joensuu,Aki Vehtari,Jaakko Riihimäki,Toshirou Nishida,Sonja E. Steigen,Peter Brabec,Lukáš Plank,Bengt Nilsson,Claudia Cirilli,Chiara Braconi,Andrea Bordoni,Magnus K. Magnusson,Zdenek Linke,Jozef Sufliarsky,Massimo Federico,Jon G. Jonasson,Angelo Paolo Dei Tos,Piotr Rutkowski +17 more
TL;DR: Although the modified NIH classification is the best criteria to identify a single high-risk group for consideration of adjuvant therapy, the prognostic contour maps resulting from non-linear modelling are appropriate for estimation of individualised outcomes.
Journal ArticleDOI
Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO
Jean-Yves Blay,Sylvie Bonvalot,Paolo G. Casali,Haesun Choi,Maria Debiec-Richter,A. P. Dei Tos,Jean-François Emile,Alessandro Gronchi,Pancras C.W. Hogendoorn,Heikki Joensuu,Axel Le Cesne,Joan Mac Clure,Joan Maurel,Ninna Nupponen,Isabelle Ray-Coquard,Peter Reichardt,Raf Sciot,Sigrid Stroobants,Martine Van Glabbeke,Allan T. van Oosterom,George D. Demetri,Ianis Boukovinas,Pierre Meeus,Jim Janinis,Rosella Bertulli,Maurizio Colecchia,Antonella Messina,Elena Tamborini,Seiichi Hirota,Toshirou Nishida,Javier Martin,Andres Poveda,Rafael Ramos,Louis Guillou,Serge Leyvraz,Mike Leahy,Christopher L. Corless,Ronald P. DeMatteo,John Zalcberg,Dolores Knufer,Aage Schultz,Ian Judson,Béatrice Fervers,Binh Bui,Frits van Coevorden,Robert S. Benjamin,Robert G. Maki,Jaap Verweij,Ole S. Nielsen,Michael Heinrich,Bert Van Geel,Larry Baker,Margaret von Mehren,Thor Alvegård,Jean Michel Coindre,Karen H. Antman,Peter Hohenberger,Kirsten Sundby-Hall,Piotr Rutkowski +58 more
TL;DR: In a substantial proportion of patients, stable disease and even increase in tumor size may be associated with pathologic response to imatinib therapy, and available survival data indicate that the survival of these patients is similar to that of patients with conventional tumor response.
Journal ArticleDOI
Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors
Seiichi Hirota,Akiko Ohashi,Toshirou Nishida,Koji Isozaki,Kazuo Kinoshita,Yasuhisa Shinomura,Yukihiko Kitamura +6 more
TL;DR: The gain-of-function mutations of PDGFR alpha appear to play an important role in development of GISTs without KIT mutations.